Anandita Agarwala
Overview
Explore the profile of Anandita Agarwala including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
512
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Agarwala A, Satish P, Ma T, Ravindranathan P, Vajramani A, Balarbar N, et al.
JACC Adv
. 2025 Jan;
3(12):101349.
PMID: 39817092
Background: Despite implementation of preventive interventions targeting cardiovascular disease (CVD), atherosclerotic CVD (ASCVD) remains a major public health concern in the South Asian (SA) population. Objectives: The purpose of this...
2.
Chavez-Ecos F, Chavez-Ecos R, Vergara Sanchez C, Chavez-Gutarra M, Agarwala A, Camacho-Caballero K
Front Cardiovasc Med
. 2024 Oct;
11:1420274.
PMID: 39376625
Introduction: mHealth apps (MHA) are emerging as promising tools for cardiovascular risk assessment, but few meet the standards required for clinical use. We aim to evaluate the quality and functionality...
3.
Spitz J, Agarwala A
J Am Coll Cardiol
. 2024 Aug;
84(9):798-800.
PMID: 39168565
No abstract available.
4.
5.
Patel J, Agarwala A, Bhatt D
JACC Adv
. 2024 Jun;
2(1):100168.
PMID: 38939025
No abstract available.
6.
Agarwala A, Dixon D, Gianos E, Kirkpatrick C, Michos E, Satish P, et al.
J Clin Lipidol
. 2024 Jun;
18(5):e664-e684.
PMID: 38824114
Cardiovascular disease (CVD) is the leading cause of death among women and its incidence has been increasing recently, particularly among younger women. Across major professional society guidelines, dyslipidemia management remains...
7.
Hayat J, Shah N, Agarwala A, Khan M, Butler J
Curr Atheroscler Rep
. 2024 May;
26(8):341-351.
PMID: 38809399
Purpose Of Review: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are gaining importance due to their effects on cardiovascular parameters. This review discusses the findings of dedicated cardiovascular outcome trials of GLP-1RAs...
8.
Satish P, Avenatti E, Patel J, Agarwala A
Prog Cardiovasc Dis
. 2024 May;
84:34-42.
PMID: 38710313
Cardiovascular disease (CVD) is the leading cause of death in women worldwide and the lifetime risk of CVD in women is similar to men. However, the pathophysiology of CVD varies...
9.
10.
Agarwala A, Asim R, Ballantyne C
Curr Atheroscler Rep
. 2024 Mar;
26(5):147-152.
PMID: 38536608
Purpose Of Review: In this review, we will discuss the data from early clinical studies of MK-0616 and summarize clinical trials of other oral proprotein convertase subtilisin/kexin type 9 (PCSK9)...